Beta-blockers may improve survival in epithelial ovarian cancer
the ONA take:
Beta-blockers, particularly first-generation nonselective beta-blockers, improved overall survival among patients with epithelial ovarian cancer, according to a new study published today in the journal Cancer.
For the study, researchers from The University of Texas MD Anderson Cancer Center in Houston, TX, retrospectively analyzed the medical records of 1,425 women with epithelial ovarian cancer treated between 2000 and 2010 in order to evaluate the impact of beta-blocker use during chemotherapy on overall survival.
Among 269 patients who received beta-blocker therapy, about 72% received beta-1 adrenergic receptor selective agents like atenolol, metoprolol, and bisoprolol, while the rest received nonselective beta-blockers, such as propranolol, carvedilol, and labetalol.
Results showed that median overall survival for beta-blocker and non-beta-blocker users was 47.8 months and 42 months, respectively.
Researchers found that patients receiving selective beta-1 blockers had a median overall survival of 94.9 months vs 38 months for those receiving non-selective beta antagonists.
The researchers note, however, that further studies are required before beta-blockers are recommended as adjuvant therapy in patients with ovarian cancer undergoing surgery.
Beta-blockers, particularly first-generation nonselective beta-blockers, improved overall survival among patients with epithelial ovarian cancer.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|